3rd Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy

LobbyistCovered position, as disclosed
EMILY FELDER —
STEPHEN HOLLAND New Senior Health Counsel, Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt Schrader
MAXWELL HUNTLEY New NSC, EOP, Dir Defense Policy and Strategy; HASC, Prof. Staff; Sen John Kennedy, Nat Security Adv; Rep. Rob Wittman, Sr Advisor; Rep Rob Wittman, Military LA/Defense Policy Adv; Rep Wittman, Leg Aide; Rep Wittman, LC; Rep Jack Bergman, Staff Assistant
ZACHARY PFISTER —
DAVID REID —
JOHN REISING —
ADAM STEINMETZ —
GREGORY SUNSTRUM —
DEEMA TARAZI —
ANDREW USYK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC)

Bills named: H.R. 1672 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.